Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

CD123 Market Report 2016: A Paradigmatic Target for Immunotherapeutic Treatment Modalities - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities" report to their offering.

This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment modalities. CD123, or the interleukin-3 receptor alpha subunit (IL-3Ra) is differentially and significantly overexpressed in a large proportion (up to 93 %) of patients with acute myeloid leukemia (AML) and has been identified as a marker of quiescent leukemic stem cells with very low or negligible expression in normal CD34+ progenitor cells. However, CD123 is normally expressed at low levels on some endothelial cells, monocytes, plasmocytoid dendritic cells (pDC), basophils, and myeloid progenitors. This expression profile makes CD123 an attractive surface target for novel antileukemic therapies.

This report describes the profiles of 16 different anti-CD123 immunotherapeutics based on different treatment modalities. The FDA recently acknowledged the anti-CD123 treatment approach by granting Breakthrough Therapy designation to the immunotoxin SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). SL-401 is the most advanced of 15 different anti-CD123 immunotherapeutis, seven of them are in earlier clinical development and further four are being prepared for clinical evaluation.

Clinical experience showed that the simple blockade of interleukin-3 signalling by a naked antibody was an insufficient therapeutic strategy which opened the way for generation and development of empowered anti-CD123 immunotherapeutics using emerging novel treatment modalities including:

- Fc-engineered antibodies;

- Immunotoxins;

- Antibody-drug conjugates;

- T-cell redirecting bispecific antibodies;

- Chimeric Antigen Receptor (CAR) engineered T-cells.

This report describes and analyzes the

- Target Background & Scientific Rationale

- Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics

- Clinical Experience with CD123-Targeted Treatment Modalities

- Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics

- Competitive Landscape

- Profiles of Anti-CD123 Immunotherapeutics

- Company Profiles

For more information about this report visit

Related Topics: Oncology Drugs

View source version on

Business Wire

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.